Skip to content
Triangle logo TriangleGet started
← Plasma Cell Neoplasms

NCT00579111 · STUDY IN CONTEXT

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Each patient will be classified as a success or failure. A success will be defined as engraftment of at least 35% of cells 100 days after transplant.

Source null

→

secondary · POSTED

Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-plasma-cell-neoplasms
nct id
NCT00579111
trial label
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
2
harms Count
2
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00579111
    outcome key
    om-0000
    source section id
    NCT00579111-om-0000
    source outcome index
    0
    endpoint
    Number of Patients With Successful Donor Engraftment
    endpoint definition
    Each patient will be classified as a success or failure. A success will be defined as engraftment of at least 35% of cells 100 days after transplant.
    time origin
    100 days
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00579111
    outcome key
    om-0001
    source section id
    NCT00579111-om-0001
    source outcome index
    1
    endpoint
    Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity
    endpoint definition
    Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity
    time origin
    100 days
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00579111
    outcome key
    om-0000
    arm key
    OG000
    arm label
    HLA-identical Sibling Transplant
    regimen
    Recipients of HLA identical sibling stem cell transplants
    analyzed count
    3
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00579111-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00579111
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Unrelated Matched or Single Antigen Mismatched Transplant
    regimen
    Recipients of unrelated matched or single antigen mismatched donor stem cell transplant or single antigen mismatched family donor stem cell transplants
    analyzed count
    1
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00579111-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00579111
    outcome key
    om-0001
    arm key
    OG000
    arm label
    HLA-identical Sibling Transplant
    regimen
    Recipients of HLA identical sibling stem cell transplants
    analyzed count
    3
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00579111-om-0001#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00579111
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Unrelated Matched or Single Antigen Mismatched Transplant
    regimen
    Recipients of unrelated matched or single antigen mismatched donor stem cell transplant or single antigen mismatched family donor stem cell transplants
    analyzed count
    1
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00579111-om-0001#groups/OG001
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00579111
    harm key
    EG000
    source section id
    NCT00579111-ae
    event group key
    EG000
    event group label
    HLA-identical Sibling Transplant
    serious affected
    2
    serious at risk
    3
    other affected
    0
    other at risk
    3
    frequency threshold
    5
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00579111
    harm key
    EG001
    source section id
    NCT00579111-ae
    event group key
    EG001
    event group label
    Unrelated Matched or Single Antigen Mismatched Transplant
    serious affected
    0
    serious at risk
    1
    other affected
    0
    other at risk
    1
    frequency threshold
    5
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice